Key facts
- Notable investors include Fujian Huaxing Venture Capital.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Guoruikang
- ·The full record, as it builds
Funding rounds
No funding rounds for Guoruikang are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Guoruikang
Developer of advanced biotechnological platforms designed for disease detection and health management. The company offers proprietary RNA real-time isothermal amplification detection technology, multiplex RNA amplification platforms, and a range of innovative pathogen RNA detection products, enabling healthcare providers, diagnostic laboratories, and patients to comprehensive molecular diagnostics that enhance clinical decision-making and disease control.
- Sector
- Healthcare
- HQ
- Chengmai, China
- Founded
- 2022
- Ownership
- Privately Held (backing)
Guoruikang doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Guoruikang shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Guoruikang in its N-PORT filings yet. We sweep new filings monthly.